Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
10
datasets available to search
ShareScore release 0.9.0
Dataset results
10 results for “Dysferlinopathy”
rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies
ClinicalTrials.gov study NCT02710500. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Deflazacort in Dysferlinopathies
ClinicalTrials.gov study NCT00527228. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Clinical Outcome Study for Dysferlinopathy
ClinicalTrials.gov study NCT01676077. IPD Sharing: Not stated. Countries: 9. Publications: 3.
Clinical, Immunological, Morphological and Genetic Characteristics of Patients With Dysferlinopathy (LGMD R2) in the RF
ClinicalTrials.gov study NCT04824040. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Data from: Assessment of disease progression in dysferlinopathy – a one year cohort study
Objective: To assess the ability of functional measures to detect disease progression in dysferlinopathy over 6 months and 1 year. Methods: 193 patients with dysferlinopathy were recruited to the Jain Foundation's International Clinical Outcome Study for Dysferlinopathy. Baseline, 6 months and 1 year assessments included: adapted North Star Assessment (a-NSAA), Motor Function Measure (MFM-20), timed function tests, 6 minute walk test (6MWT), Brooke Scale, Jebsen Test, manual muscle testing (MMT) and hand-held dynamometry (HHD). Patients also completed the ACTIVLIM questionnaire. Change in each measure over 6 months and 1 year was calculated and compared between disease severity (ambulant (mild, moderate or severe based on a-NSAA score) or non-ambulant (unable to complete a 10m walk)) and clinical diagnosis. Results: The functional a-NSAA test was the most sensitive to deterioration for ambulant patients overall. The a-NSAA score was the most sensitive test in the mild and moderate group while 6MWT was most sensitive in the severe group. The 10m walk test was the only test showing significant change across all ambulant severity groups. In non-ambulant patients, the MFM domain 3, wrist flexion strength and pinch grip were most sensitive. Progression rates did not differ by clinical diagnosis. Power calculations determined that 46 moderately affected patients are required to determine clinical effectiveness for a hypothetical 1 year clinical trial based on the a-NSAA as a clinical endpoint. Conclusion: Certain functional outcome measures can detect changes over 6 months and one year in dysferlinopathy and potentially be useful in monitoring progression in clinical trials.
Data from: Assessment of disease progression in dysferlinopathy – a one year cohort study
Open the record for dataset details and reuse information.
Observational Cohort Study of Dysferlinopathy in China
ClinicalTrials.gov study NCT07035145. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Dysferlinopathy Protein in Peripheral Blood Monocytes.
ClinicalTrials.gov study NCT06507215. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Gene expression profiling in dysferlinopathies using a dedicated muscle microarray
GEO Series GSE3022. Homo sapiens. 10 samples. Type: Expression profiling by array.
Muscle Hypertrophy Induced by Myostatin Inhibition Accelerates Degeneration in Dysferlinopathy
GEO Series GSE62945. Mus musculus. 18 samples. Type: Expression profiling by array.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.